chufangao/CTO huggingface dataset:
Clinical trial NCT04332549: To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Official title: A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Suspension (PICS) in Subjects With Locally Recurrent or Metastatic Breast Cancer.
Sponsor: Sun Pharma Advanced Research Company Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: After meeting with the FDA, SPARC concludes a BE study will not be required
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-27
Primary completion date: 2021-01-28
Completion date: 2021-01-28
Plan to share individual participant data: NO
Clinical trial NCT05017103: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Official title: A Phase II Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Undifferentiated Pleomorphic Sarcoma (SiARa-UPS)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: All subjects have finished their final visits and follow-up,
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-13
Primary completion date: 2024-02-20
Completion date: 2024-02-20
Clinical trial NCT02404506: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
Official title: Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial was prematurely terminated as of 22.07.2021 as per SAKK board decision board decision from 14th of November 2020. The trial was terminated after the primary endpoint was analyzed, which was the case end of December 2020.
Enrollment: 78.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-08-17
Primary completion date: 2020-12-30
Completion date: 2021-07-22
Plan to share individual participant data: NO
Clinical trial NCT03755154: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Official title: Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Sponsor: Servier (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns.
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-17
Primary completion date: 2023-11-06
Completion date: 2023-11-06
Plan to share individual participant data: YES
IPD sharing description: Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.~Access can be requested for all interventional clinical studies:~* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.~In addition, access can be requested for all interventional clinical studies in patients:~* sponsored by Servier~* with a first patient enrolled as of 1 January 2004 onwards~* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.
IPD access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Clinical trial NCT04984330: Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Official title: Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Acronym: STARR
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Funding withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-31
Primary completion date: 2023-06-30
Completion date: 2024-06-30
Plan to share individual participant data: NO
Clinical trial NCT03722966: Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
Official title: A Comparison of the Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy Versus Varenicline Alone for Smoking Cessation: a Pilot Study
Sponsor: University of Oklahoma (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Following the Chantix recall, Pfizer stopped providing medication for the study and and new study enrollments were discontinued.
Enrollment: 34.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-01-07
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Limitations and caveats: The study was discontinued early due to the recall of varenicline.
Plan to share individual participant data: NO
Clinical trial NCT02546999: Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
Official title: Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
Acronym: WE
Sponsor: St. Olavs Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2021-10-15
Completion date: 2021-10-15
Clinical trial NCT04331899: Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
Official title: A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19
Acronym: COVID-Lambda
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-25
Primary completion date: 2020-08-14
Completion date: 2021-05-06
Plan to share individual participant data: YES
IPD sharing description: Sharing of generated and analyzed datasets.
IPD time frame: The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository
IPD access criteria: Full access
Clinical trial NCT02899299: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Official title: A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Acronym: CheckMate743
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 605.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-29
Primary completion date: 2020-03-25
Completion date: 2023-04-28
Clinical trial NCT02200770: N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Official title: A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 231.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-01
Primary completion date: 2018-10-26
Completion date: 2020-11-06
Baseline population: The Intent-to-treat (ITT) population included all participants who were randomized, received any study drug, and grouped according to their randomized treatment.
Limitations and caveats: In the safety follow-up period (SFP), only 1 participant from 'Placebo/Inebilizumab' arm rolled over to SFP and no participant from 'Inebilizumab /Inebilizumab' arm rolled over to SFP. For EudraCT result posting, a study period with any one of the arm with zero participants started is not acceptable (EudraCT limitation). Therefore, not included SFP in 'Participant Flow' section to keep the data consistent across registry portals.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT02446145: A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients
Official title: A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients ≥65 Years of Age Not Eligible for Intensive Chemotherapy
Acronym: DELTA
Sponsor: Technische Universität Dresden (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an acceptable time line. Furthermore, new drugs have recently been licensed resulting in alternative treatment regimens with a better prognosis.
Enrollment: 132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-05-31
Primary completion date: 2020-12-26
Completion date: 2023-01-25
Clinical trial NCT04156204: Immunosuppressant Medication Dosed Daily After Kidney Transplant
Official title: Kidney Immunosuppression Dosed Daily Only (KIDDO) - A Pilot Study
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Discontinuation of study due to site staffing and resources available to conduct the study
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-20
Primary completion date: 2020-11-27
Completion date: 2020-11-27
Plan to share individual participant data: NO
Clinical trial NCT04338074: TXA and Corona Virus 2019 (COVID19) in Outpatients
Official title: Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients
Acronym: TCOutpatient
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-04-21
Completion date: 2021-04-21
Plan to share individual participant data: NO
Clinical trial NCT04430348: PTX-35 in Patients With Advanced Solid Tumors
Official title: PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care
Sponsor: Heat Biologics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Absence of immunological response
Enrollment: 22.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-06-04
Primary completion date: 2022-11-02
Completion date: 2023-06-15
Plan to share individual participant data: NO
Clinical trial NCT03375606: Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects
Sponsor: CSL Behring (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor decided to terminate this study in favor of development of subcutaneous administration.
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-10
Primary completion date: 2020-06-22
Completion date: 2020-06-22
Plan to share individual participant data: NO
Clinical trial NCT03719612: DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Official title: A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-Enhanced 2D-Echo and Magnetic Resonance Imaging
Acronym: BENEFIT2
Sponsor: Lantheus Medical Imaging (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-28
Primary completion date: 2020-01-09
Completion date: 2020-01-09
Baseline population: Baseline data are calculated based on Safety Population
Plan to share individual participant data: NO
Clinical trial NCT03610282: EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation
Official title: Electroencephalogram Study of Intravenous Methylphenidate-Induced Emergence From Propofol Sedation
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: We have decided to withdraw the study prior to enrollment of the first participant in order to pursue other research studies.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-30
Primary completion date: 2020-11-30
Completion date: 2021-11-30
Clinical trial NCT04142554: Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
Official title: Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Negative or HER2-Positive Breast Cancer
Acronym: LCCC1820
Sponsor: UNC Lineberger Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funding withdrawn from funding source.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-01
Primary completion date: 2020-09-07
Completion date: 2020-09-07
Plan to share individual participant data: NO
Clinical trial NCT04364763: A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Official title: A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Sponsor: Renibus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment feasibility
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-05
Primary completion date: 2021-09-02
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT03545243: PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia
Official title: Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-23
Primary completion date: 2020-03-08
Completion date: 2020-09-22
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03482011: A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Official title: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Acronym: OASIS-1
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 530.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-24
Primary completion date: 2019-03-21
Completion date: 2020-01-16
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03988842: Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Official title: Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Acronym: SAFE-LYSE
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19 pandemic
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-25
Primary completion date: 2020-04-05
Completion date: 2020-04-05
Baseline population: The study was closed prematurely due to covid-19. Unblinding was not done and analysis was not performed.
Limitations and caveats: Enrollment was held and study closed prematurely due to COVID-19 pandemic. We were otherwise hopeful to enroll and complete all assessments for this study.
Plan to share individual participant data: NO
Clinical trial NCT03829501: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
Official title: A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 As Single Agent and in Combination with Anti-PD-L1 (atezolizumab) in Adult Patients with Selected Advanced Malignancies
Sponsor: Kymab Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Enrollment: 222.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-28
Primary completion date: 2024-10-03
Completion date: 2024-10-03
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at https://vivli.org
Clinical trial NCT03361501: A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
Official title: A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia
Acronym: TRILOGY 2
Sponsor: Acasti Pharma Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 278.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-01
Primary completion date: 2019-09-24
Completion date: 2020-01-09
Plan to share individual participant data: NO
Clinical trial NCT03271489: Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Official title: A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 478.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-04
Primary completion date: 2024-06-28
Completion date: 2024-06-28
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03217812: A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Official title: A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-23
Primary completion date: 2020-07-02
Completion date: 2024-03-08
Clinical trial NCT02824575: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Official title: Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-31
Primary completion date: 2021-12-27
Completion date: 2021-12-27
Plan to share individual participant data: NO
Clinical trial NCT05367661: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
Official title: A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers
Sponsor: Chinook Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 88.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-04-08
Primary completion date: 2023-04-19
Completion date: 2023-04-19